ENGNHIGH SIGNALFINANCIAL10-K

ENGN's financial position deteriorated dramatically with cash burning from $173M to $50M while R&D expenses more than doubled and losses increased 113%.

The company is burning through cash at an accelerated rate with only $50M remaining versus $173M a year ago, while simultaneously doubling R&D spending to $94.5M and posting net losses of $117M. This cash depletion trajectory combined with massive expense increases suggests potential funding challenges ahead and raises questions about runway sustainability.

Comparing 2025-12-22 vs 2024-12-19View on EDGAR →
FINANCIAL ANALYSIS

ENGN's financial profile shows severe deterioration across all key metrics, with cash reserves plummeting 71% to $50M while R&D expenses surged 147% to $94.5M, driving net losses to balloon 113% to $117M. Operating cash outflows more than doubled to $99M while current liabilities increased 118%, creating a concerning liquidity picture. The simultaneous cash burn acceleration and expense explosion suggests the company may face near-term funding pressures despite having $50M in cash remaining.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+248.1%
$1.4M→$5.0M

Interest expense surged 248.1% — significant debt increase or rising rates materially impacting earnings.

R&D Expense
P&L
+146.6%
$38.3M→$94.5M

R&D investment increased 146.6% — signals commitment to future product development, though near-term margin impact.

Current Liabilities
Balance Sheet
+118.1%
$14.7M→$32.0M

Current liabilities surged 118.1% — significant near-term obligations; verify ability to meet short-term debt.

Net Income
P&L
-112.7%
-$55.1M→-$117.3M

Net income declined 112.7% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-105.5%
-$48.3M→-$99.2M

Operating cash flow fell 105.5% — earnings quality concerns; investigate working capital changes and non-cash items.

Operating Income
P&L
-97.7%
-$62.3M→-$123.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
-71%
$173.0M→$50.2M

Cash declined 71% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Capital Expenditure
Cash Flow
+60.5%
$925K→$1.5M

Capital expenditure jumped 60.5% — major investment cycle underway; assess returns on deployment.

Total Liabilities
Balance Sheet
+39.4%
$38.6M→$53.8M

Liabilities grew 39.4% — significant increase in debt or obligations, assess impact on financial flexibility.

Stockholders Equity
Balance Sheet
-38.5%
$272.6M→$167.7M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

LANGUAGE CHANGES
NEW — 2025-12-22
PRIOR — 2024-12-19
ADDED
The number of the registrant s Common Shares outstanding as of December 17, 2025 was 66,984,661 .
If our internal controls over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information and may lead to a decline in the trading price of our common stock.
We depend on our executive team and key personnel, and if we lose one or more of our executive officers or key employees or are unable to attract and retain highly skilled employees, such events could harm our business.
As a result of the Reverse Recapitalization, the Company became a publicly traded company and listed its Common Shares and Warrants on the Nasdaq Global Market under the symbols ENGN and ENGNW, respectively, commencing trading on November 1, 2023, with enGene Inc.
Overview We are a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC).
+7 more — sign up free →
REMOVED
The number of the registrant s million Common Shares outstanding as of December 16, 2024 was 50,976,676 .
We identified material weaknesses in our internal control over financial reporting and our management has determined that our current internal control over financial reporting is not effective.
If we are unable to remedy these material weaknesses, or if we fail to establish and maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may continue to determine that our internal control over financial reporting is not effective, which could adversely impact our investors confidence and the price of our Common Shares.
We depend on our executive team, and if we do not successfully manage the previously announced transitions of our Chief Executive Officer and other executive officers, or if we lose one or more of our executive officers or key employees or are unable to attract and retain highly skilled employees, such events could harm our business.
As a result of the Reverse Recapitalization, the Company became a publicly traded company, and listed its Common Shares and Warrants on the Nasdaq Global Market under the symbols ENGN and ENGNW, respectively, commencing trading on November 1, 2023, with Old enGene, a subsidiary of the Company, continuing the existing business operations.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →